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Abstract: Rhenium-188 (188Re) is a high energy beta-emitting radioisotope of widespread interest for use in nuclear 
medicine, oncology and other therapeutic applications. High energy beta emission (16.9 hour half-life) with Emax 2.12 
MeV and gamma emission at 155 keV (15 %) are key factors for effective therapy and imaging for tissue kinetics and 
dosimetry evaluation. Moreover, on-demand availability of 188Re in a highly reproducible manner from the 188W/188Re 
generator system is an important capability for installation in a hospital-based or a central radiopharmacy for cost 
effective availability of no-carrier-added (NCA) 188Re. Because of the long 69.7 day half-life of the188W generator parent, 
the use of well-established post 188Re elution specific volume concentration technology allow generators to have a 
useful/predictable operational shelf-life of a few months. This paper provides a holistic review of the development, 
availability and use of the 188W/188Re generator prototypes. 
Keywords: Beta emitters, Bolus concentration, Radionuclide generator, Radionuclide therapy, Rhenium-188, 
Tungsten-188. 
1. INTRODUCTION 
The history describing the initial discovery of 
technetium (“masurium”) and rhenium in Germany 
during the 1930’s involved the use of minimal technical 
tools but great effort and impressive technical insight 
[1]. Rhenium (Re, element 75) was first isolated and 
identified by German scientists Ida Noddack-Tacke and 
Walter Noddack while working in Strasbourg, who 
named this new element after the Roman Latin 
designation “rhenus” for the river Rhine [1]. Of course 
during that time investigators had not envisaged the 
important future applications which technetium-99m 
(99mTc) and 188Re would subsequently play for diagno- 
sis and therapy in the future field of nuclear medicine.  
Over the last three decades interest in the 
therapeutic use and development of 188Re-labeled 
radiopharmaceuticals has persisted with broad interest 
on an international basis, and a number of reviews 
have discussed this progress [2-8]; [See Shinto and 
Knapp, this issue of IJNMR]. Development of high yield 
and easy to use 188W/188Re generators has provided 
NCA 188Re to pursue new radiolabeling strategies and 
the development, evaluation and clinical use of a 
variety of therapeutic radiopharmaceuticals as 
described in the following paper. Although embedded 
in the literature and not widely known, early preliminary 
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studies, however had actually described 
prototype188W/188Re generators to obtain 188Re for the 
wrong reasons, since 188Re had been promoted as a 
diagnostic radioisotope during the period when the 
99Mo/99mTc generator was initially being introduced  
[9-11], apparently without regard to consideration of 
radiation dose. Initial projected studies with 188Re 
available from an early prototype zirconium-based 
generator had thus been proposed use for imaging [9], 
although the gamma decay is accompanied by 
emission of high energy beta particles. Use of 188Re for 
diagnostic applications would of course result in 
unacceptable radiation dose to both targeted and non-
targeted tissues. 
 
Figure 1: Tungsten-188 is reactor produced by double 
neutron capture on enriched 186W targets. Subsequent 
processing provides 188Re solution for preparation of the 
188W/188Re generators. 
The 188W/188Re “chromatographic-type” generator 
prototypes (Figure 1) utilize loading of the processed 
188W divalent anion (WO4-2, half-life 69 days) which is 
obtained by reactor double neutron capture production 
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on enriched 186W targets [12-21]. The irradiated targets 
are processed and the 188W tightly bound as tungstic 
acid to an adsorbant. The 188Re (half-life 16.9 hours) 
generated as the perrhenate (ReO4-1) monovalent 
anion by beta decay of 188W is not tightly bound to the 
adsorbant, and readily removed from the generator by 
elution, for instance, with physiological saline. 
Because of the relative radioactive half-lives, the 
188Re daughter is quickly re-formed by continuous 
ingrowth from 188W decay after elution of the bolus from 
the 188W/188Re equilibrium mixture (Figure 2, left panel). 
On a daily 24 hour elution basis, approximately 62% of 
the equilibrium yield of 188Re is eluted, indicating that 
about 600 mCi can initially be eluted from a 1 Ci 
188W/188Re generator at equilibrium. Data obtained from 
successive elution of a 1 Ci generator [4] summarized 
in Figure 2 (right panel) demonstrate the reproducibly 
high 188Re yields with low 188W parent breakthrough for 
elution over a two month period. 
2. ADVANTAGES OF THERAPEUTIC USE OF 
RHENIUM-188 
The availability of high yield NCA 188Re, on demand, 
from the 188W/188Re radionuclide generator system was 
a central practical consideration which had stimulated 
interest in the use of 188Re for a variety of therapeutic 
applications, which are discussed in detail in an 
accompanying paper in this issue of IJNMR. 
Radiopharmaceutical development beginning in the 
1980’s has subsequently blossomed into a variety of 
clinical applications. Figure 3 (left panel) further 
illustrates the theoretical elution characteristics and 
multi-cycling of the generator for four elution cycles 
demonstrating the slow decay of 188W. The curves for 
188W decay, 188Re in growth and 62% daily 188Re 
elution yields are shown in Figure 3 (right panel). 
 
Figure 2: Left - A major advantage for radiopharmacy use of the 188W/188Re generator is the relatively rapid in growth of 188Re 
from 188W decay following elution which provides 62% of the maximal 188Re in growth available every 24 hours. Right – 
Generator operational is consistent and predictable over a long time period with high 188Re yields and low 188W parent 
breakthrough. 
 
Figure 3: In growth curves for 188Re generated from decay of 188W. Left - four successive cycles following 24 elution of 188Re 
(half-life 16.9 hours) illustrating daily in growth and availability of high daily activity levels of 188Re. Right – The slow decay of 
188W (69 day half-life) will provide high daily levels of 188Re. Even after four months (1.7 decay half-lives of 188W) a 1 Ci 
generator will decay to only 300 mCi. Although the saline bolus elution volume is essentially the same for the operational shelf-
life of the generator, post elution concentration can provide constant specific volume (mCi/mL) levels of 188Re eluted throughout 
the generator shelf-life. 
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3. DEVELOPMENT OF THE TUNGSTEN-
188/RHENIUM-188 GENERATOR 
Although a variety of 188W/188Re generator 
prototypes have been described in the literature  
[12-49], the alumina-based generator system has been 
demonstrated as the most simple, reliable and is widely 
used to obtain 188Re for clinical use [12, 22-26, 30-32]. 
Other variations which have been described and 
include 188W/188Re generators based on zirconium 
oxide/zirconia [27, 37-38, 41-42], gel-type technology 
[44-46], electrochemistry [43], extraction centrifuge 
techniques [40], thermo-chromatography, use of high 
capacity adsorbent-based, nanomaterial-based and 
solvent extraction, but apparently none of these 
systems have been further evaluated for routine use of 
188Re in a clinical setting. The first evaluation of the 
generator separation of no-carrier-added 188Re from 
the 188W parent using a generator-based system was 
explored in 1966 [9-10]. This system involved use of 
188W bound to the zirconium oxide adsorbant eluted 
with the methyl ethyl ketone (MEK) organic solvent. 
Apparently not further evaluated, this system was 
impractical for providing 188Re for clinical evaluation of 
188Re-based therapeutic agents and further 
development and use did not mature. This approach 
was impractical, since eluant evaporation, subsequent 
manipulation and re-dissolution of 188Re in a system to 
allow labeling of the desired targeting agent presented 
technical and quality control challenges. 
In addition to the alumina-based systems, one area 
of 188W/188Re generator development which had been 
of extensive earlier interest involved the use of “gels,” 
which consist of homogeneous admixture of 188W with 
the chromatographic adsorbent prior to generator 
column loading, as opposed to the adsorptive binding 
of 188W with the initial volume of the alumina adsorbent 
[41, 44-46]. The “gel” technology allows the use of low 
specific 188W - or in the case of the 99Mo/99mTc 
generator – low specific activity 99Mo produced by 
irradiation of enriched 98Mo [i.e. 98Mo(n,γ)99Mo]. 
Although significant research efforts had been reported 
evaluating this technology, the challenges associated 
with reproducible generator fabrication and 
performance, and other technical issues, resulted in no 
further broader evaluation and clinical introduction of 
this type of generator. In the same context, an 
alternative technology focused on the liquid extraction 
[47-48] and subsequent radiolabeling use of 188Re from 
188W/188Re mixtures has only evidently been evaluated 
in a cursory manner [9-10].  
The most practical strategy then focused on further 
development of the acidic alumina-based generator 
system similar to the 99Mo/99mTc generator, allowing 
generator elution with saline which would represent a 
medium for subsequent substrate radiolabeling, also 
representing a physiologically compatible medium for 
intravenous administration. Subsequently, our ORNL 
program and other investigators focused on the use of 
an alumina-based generator system with saline elution, 
which provided a convenient approach to obtain 188Re-
perrhenate directly from generator elution without 
subsequent complex eluent manipulation, similar to the 
elution of 99mTc from the alumina-based 99Mo/99mTc 
generator system. However, an important difference for 
the 188W/188Re alumina-based generator is the 
requirement for much larger amounts of the alumina 
adsorbent, which is required for binding of the much 
lower specific activity 188W, reactor produced by 
neutron irradiation of enriched 186W targets, compared 
with 99Mo, available NCA from isolation from 235U 
fission product mixtures. This necessity for the use of 
large amounts of the alumina adsorbant for 188W 
binding results in the requirement for higher eluant and 
thus bolus volumes, as discussed in more detail below, 
ideally requiring the use of technologies for post elution 
concentration of the 188Re generator bolus. These post 
elution concentration technologies described later are 
also useful for concentration of the high saline volume 
99mTc boluses obtained from 99Mo/99mTc generators 
prepared from (n,γ) 99Mo. 
4. IMPORTANCE OF AVAILABILITY OF TUNGSTEN-
188 
In contrast to the availability of very high specific 
activity microscopic levels of 99Mo produced at about 
6% yield via nuclear fission of uranium-235 (235U), 188W 
is produced by neutron capture on macroscopic levels 
of enriched 186W (Figure 1). Since the 188W product and 
186W target atoms cannot be separated by any cost 
effective/practical strategy, the specific activity of 188W 
is significantly lower (about 104) than 99Mo due to 
fission mixture contamination with other Mo isotopes. 
Although the specific activity is also affected by the 
irradiation period, post irradiation decay and the 235U 
enrichment, values are still very high at levels 
estimated to be > 2 x 104 Ci/gram Mo, compared to a 
maximum of about only about 10 Ci/gram W, based on 
the 186W target contamination. One unfortunate, yet 
established certainty, is that only a limited number of 
high flux reactors are available for production of 188W 
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with specific activity value approaching the maximum 
expected of approximately 10 Ci/gram 186W (ORNL 
High Flux Isotope Reactor, Oak Ridge, TN USA; SM-3 
Reactor, Dimitrovgrad, Russian Federation; BR2 
Reactor, Mol, Belgium). However, because of the long 
useful 188W/188Re generator shelf-life and availability, 
and post irradiation recovery possibilities for enriched 
186W for re-use as irradiation targets, experience over 
the last two decades has demonstrated that sufficient 
188W can be produced to meet the expected 
international clinical demands [19-20, 23]. Because of 
the relatively low 188W specific activity, relatively large 
amounts of the alumina column adsorbant are required 
for adequate generator loading/binding of the 
processed 188W tungstic acid. The 188W/188Re generator 
thus requires much higher alumina levels than required 
for clinical scale multi-Ci99Mo generators. This 
necessity results in much higher generator void 
volumes, resulting in significantly higher saline elution 
volumes and lower specific volume (activity/volume) of 
188Re eluants. 
5. AVAILABILITY OF TUNGSTEN-188 AND W-
188/RE-188 GENERATORS 
For the expanded clinical utilization of 188Re a 
crucial issue which must be addressed is the 
dependable, routine availability of GMP-produced 
188W/188Re generators. Table 1 summarizes information 
for 188W/188Re generators which are currently, or which 
have been previously, available. All of these generator 
prototypes are alumina-based systems and eluted with 
physiological saline, with reported high188Re yields of 
90-95% and with low 188W parent breakthrough of 10-4-
10-3 %/bolus. Information included in this summary is 
based on data available via the Internet. All these 
generator systems are alumina-based, have 
reproducible high 188Re yields, low 188W parent 
breakthrough/bolus and long useful half-lives. The 
188W/188Re generators are available in high activity 
levels from the three manufacturers described in  
Table 1. Although these three prototypes are 
manufactured under quality conditions, only the Rhein 
Eo generator equipped with the post elution 188Re 
concentration cassettes from IRE-Elit in Belgium, is 
Table 1: Principal Suppliers of Tungsten-188/Rhenium-188 Generators 
Institution/ Organization Generator Designation 
Activity 
Levels Comment/Special Features, Web Page Contacts 
Examples of Currently Available W-188/Re-188 Generators 
IRE-Elit, Fleurus, Belgium Rheni Eo 0.5-1.5 Ci 
Sterile GMP system. Active pharmaceutical product (API). Fully automated 
system available with convenient plug-in cassette unit for post elution188Re 
concentration 6 month shelf-life. 
http://www.ire.eu/ouractivities/radiopharmaceutical-products. 
Also reported to be distributed by Iso Solutions and Radio Medix Inc. 
Isotope Technologies Munich 
(ITM),Germany 
188W/188Re 
Generator 
2.7 Ci  
 
Non-sterile system. < 10 mL elution volume, >135/mL. Several month shelf-
life. For laboratory research purposes only. Reported that post concentration 
of 188Re not required. 
<http://www.isotope-technolgies-munich.com/products/radionuclides/ 
188w188re-generator/> 
JSC “SSC RF-IPPE, 
Obninsk, Russian Federation GREN-1 <1.0 Ci 
Non-sterile system. Registration certificate No. FS, 02032006/5395-06 
issued by the Ministry of Health of the Russian Federation. Process 
regulation PR No. 35.92-3/61-01 for the production of generators 
<http://www.ippe.ru/prod/isotope/isot-1-3en.php> 
Key Examples of Previously Available W-188/Re-188 Generators 
Oak Ridge National 
Laboratory (ORNL), Oak 
Ridge, TN, USA 
188W/188Re 
Generator Up to 3 Ci 
May still be available non GMP on special order >500 generators provided 
internationally during the 1986-2011 period. Bolus concentration technology 
provided. Non-sterile GMP production under FDA Drug Master. File #22577 
(Type 2). Active pharmaceutical ingredient (API). Indefinite useful shelf-life 
of several months. ORNL Isotope Business Office, Oak Ridge, TN. Tel. 1-
(865) 574-6984; FAX 1-(865) 574-6986 
Polatom, Otwock, Poland  0.100-0.810 Ci 
No longer available since about 2005. Generator was fitted with 
bacteriological filter. At least 6 month shelf-life 
MAP Medical Technologies, 
Tikkakoski, Finland  0.5-1.0 Ci 
No longer available since about 2003. Produced for IAEA-funded projects in 
conjunction with Mol Reactor and ORNL 
 
Generator Availability of 188Re for Therapy International Journal of Nuclear Medicine Research, 2017    7 
apparently the only system available as a sterile GMP 
device approved for clinical use. The other generators 
are evaluated in house prior to acceptance for human 
use. The non-sterile GMP generators previously 
supplied from ORNL are evidently no longer available 
(Table 1), since the manufacturing facility is no longer 
in operation. The sterile, pyrogen-free GMP 
manufactured generators which had been previously 
manufactured at POLATOM, are also no longer 
available. Evidently the high production and delivery 
costs of processed 188W from the Dimitrovgrad facility 
and the less than expected modest generator sales are 
factors which resulted in removal of this generator from 
the POLATOM product line. 
Although availability of high specific activity 188Re 
from the 188W/188Re generator is the preferred cost-
effective route, it is surprising that the well-established 
“direct” reactor production and facile post irradiation 
processing and dispensing of high specific activity 
188Re by irradiation of enriched 187Re [187Re (n,γ)188Re] 
(Figure 1) has not been pursued for availability of this 
therapeutic radionuclide for radiopharmaceutical 
preparation for clinical applications. There are many 
research reactors throughout the world, including many 
developing countries, which have sufficient thermal 
neutron flux for production of 188Re with sufficient 
specific activity by this route. Target preparation, 
processing and 188Re product dispensing are straight 
forward and the 16.9 hour half-life of 188Re would allow 
delivery even beyond local sites. All of the alumina-
based generators summarized in Table 1 have been 
reported – primarily in promotional product information 
available on the Internet – to have predictable 
operation with “long” useful shelf-lives to provide 188Re 
in about 95% yield and with low 188W breakthrough 
values of < 10-3 %/188Re bolus. 
6. ISSUES ASSOCIATED WITH AVAILABILITY AND 
UTILIZATION OF THE W-188/RE-188 GENERATOR 
IN THE RADIOPHARMACY 
Because of the low specific activity of 188W, the 
188W/188Re generators must be eluted with relatively 
high saline volumes which results in lower per volume 
bolus activity (lower activity/bolus volume) compared to 
99mTc available from the 99Mo/99mTc generator system. 
For this reason the useful elution shelf life for generator 
use can be limited – if the 188Re specific volume is a 
key issue - and much shorter than the demonstrated 
prolonged time period for generator performance of 
several months, unless post elution 188Re bolus conce- 
ntration methods are used. Important technologies 
which make routine availability of 188Re possible 
include GMP generator production, automated systems 
for generator elution and 188Re bolus concentration, 
effective chemical strategies for attachment of 188Re to 
targeting molecules and the increasing availability of 
radiolabeling “kits” for radiopharmacy preparation of 
targeted 188Re radiopharmaceuticals. Obviously, in 
addition to GMP manufacture of the 188W/188Re 
generators, the same quality programs are required for 
production of the concentration units and “kits” which 
would result in significantly higher costs to the 
expanded clinical introduction of specific188Re-labeled 
therapeutic agents. 
6.1. Post Elution Rhenium-188 Bolus Concentration 
Using Tandem Cation/Anion Columns 
Although apparently only one commercially 
available 188W/188Re generators apparently is provided 
with post elution concentration units/cassettes (Table 1; 
IRE-Elit) to obtain 188Re of sufficient specific volume for 
radiopharmaceutical radiolabeling, the use of such 
technologies is widely felt to be very effective in 
considerably extending the generator shelf-life and to 
reduce unit 188Re dose costs [50]. These systems are 
readily prepared, easy to use and are very efficient and 
effective in concentrating 188Re eluants when a higher 
specific volume is required (Figure 4). Our ORNL 
technology using a tandem silver nitrate/QMA system 
had first been reported [4, 50-57] for isolation of the 
188Re-perrhenate anion from the high volume generator 
eluant. Several alternate post elution approaches/ 
systems had subsequently been reported in the 
literature using various perrhenate trapping cartridge 
systems [58-63], but it is unclear, however, which of 
these systems have been routinely used for clinical 
application. Use of the tandem silver impregnated 
chloride trapping/perrhenate trapping column system 
represents effective access to high specific 
volume188Re solutions which has been used for a 
number of years to obtain high specific volume 188Re 
for a variety of clinical applications, including single 
center and IAEA-sponsored programs for vascular 
therapy describe here later, and for liver cancer 
therapy. Use of such disposable 188Re bolus 
concentration cartridge units using readily available 
and inexpensive components is well described [4, 53-
57], is well established and disposable 188Re bolus 
concentration systems can be provided as disposable 
packaged cassette systems with commercial 
generators [Rheni Eo, IRE Elit, Table 1].  
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This silver chloride trapping-based 188Re concentra- 
tion system is simple, cost effective method based on 
the concept for post elution trapping of the macroscopic 
levels of the chloride anion from the saline as insoluble 
silver chloride in the silver-cation column. Subsequent 
trapping of microscopic levels of the 188ReO4-
1perrhenate anion then occurs on the small QMA anion 
trapping column. Water washing followed by isotonic 
saline elution of the QMA anion column then provides 
highly concentrated levels of sodium 188Re-perrhenate. 
This simple flow through method using inexpensive 
disposable components provides high specific volume 
solutions of 188Re sodium perrhenate over the 
generator shelf-life [4-5]. 
For more cost effective extension of the useful 
shelf-life, the use of such effective concentration 
strategies is required, because of the high 188Re bolus 
volumes which are obtained from generators fabricated 
with the relatively low specific activity 188W. The high 
amounts of alumina required to bind the low specific 
activity 188W parent results in high elution volumes and 
low specific volume solutions of 188Re, because of the 
double neutron capture process and only modest 
thermal neutron cross section values - as compared 
with the very high specific activity fission-produced 
99Mo generally used for fabrication of the 99Mo/99m Tc 
generators. Only low levels of alumina are required to 
bind carrier-free fission-produced 99Mo for the 
commercially available 99Mo/99mTc generators, which 
permits low volume saline elution of the 99mTc bolus, 
thus providing high specific volume 99mTc solutions. For 
the ORNL alumina generator prototype, the 188W 
loading capacity is limited to < 50 mg W/gram alumina, 
minimizing188W parent breakthrough through repeated 
use. The 188Re specific volume (mCi/ml) eluted from a 
typical 1 Ci188W/188Re generator (14 gram alumina) 
requires a saline bolus volume of 12-15 ml. These 
values of course decrease with time (188W decay), 
providing specific volume solutions which may not be 
sufficient for "kit" labeling of tissue-specific 
radiopharmaceuticals. For this reason, post elution 
188Re concentration offers a convenient cost effective 
strategy for providing higher specific volume 188Re unit 
doses. 
Since the long useful shelf-life is an important 
aspect for use of this generator system, the availability 
of simple, efficient methods for concentration of the 
generator eluant is intuitively an important capability. 
The availability of these methods also extends the 
useful shelf-life of the generator since the specific 
volume (mCi/mL) of the generator eluate deceases as 
a result of the radioactive decay of the 188W parent. 
Use of the188W/188Re generators can be optimized for 
routine clinical use by incorporating disposable tandem 
silver cation-chloride trapping/anion-exchange columns 
to provide high specific volume 188Re solutions. The 
combined reproducible elution/concentration of 188Re is 
rapidly conducted making routine radiopharmacy use of 
a concentration system practical. 
Post elution concentration of the 188Re generator 
eluant can have important benefits since the useful 
188W/188Re generator shelf-life can be significantly 
extended to a few months (Figure 3). The possible 
benefits of post elution eluant depend on a number of 
economic and technical factors. For instance, if 
adsorption of upfront generator cost is not a major 
factor and/or if patient throughout and thus 
reimbursement are high, then the generator can be 
used during a shelf-life which is limited by the 188Re 
 
Figure 4: Schematic illustrating the basis of the tandem silver nitrate imbedded adsorbant-based silver-chloride trapping system 
for subsequent anion column trapping of the 188Re-perrhente anion for elution with low saline volume. 
Generator Availability of 188Re for Therapy International Journal of Nuclear Medicine Research, 2017    9 
eluant specific volume (mCI/mL) required. However, 
other factors which may have to be considered include 
the high cost of generator purchase and importation 
and recruitment of minimal patients for 188Re therapy. 
Other cost saving generator use optimization 
approaches which we have suggested when cost is a 
major factor also include the tandem connection of new 
generators with used generators for combined bolus 
collection and concentration in order to optimize the 
availability of 188Re. Another important issue is the 
bolus saline specific volume (mCi 188Re/mL) 
requirements for targeting agent radiolabeling or post 
elution use of 188Re. For instance, in the case of 
balloon inflation with 188Re solutions (vide infra), the 
specific volume must be very high (> 100 mCi 
188Re/mL), which generally would always require bolus 
concentration. If a large patient population can be 
treated with 188Re over a short time and costs can be 
amortized in a short time period, than in extenso 
generator shelf-life and the need for post elution 
concentration may not be major issues. All of these 
factors must be evaluated and considered for each 
facility, but in the final analysis, it has been 
demonstrated by use at many radiopharmacy/clinical 
sites that post elution concentration of 188Re is an 
effective strategy to optimize 188W/188Re generator use 
and cost. 
6.2. Availability of Chemical Strategies for 
Attachment of Rhenium-188 to Targeting Agents 
The evaluation of various useful Re oxidation states 
for radiolabeling has been evaluated and reviewed [62-
64]. Because of relative stability and facile availability, 
Re(I) (i.e. as the tricarbonyl, Re(CO)3,) [65], Re(V) (i.e. 
as DEDC) and 188Re(III)-SSS-lipiodol {SSS = 
(S2CPh)(S3CPh)2}) [63-66-67] and Re(V) (from facile 
reduction of Re(VII) with stannous ion, etc.) [62, 64] are 
the forms of 188Re obtained from chemical 
transformation of generator-derived 188Re-perhenate 
for which many other approaches have been 
developed for introduction into therapeutic targeting 
agents [68-71; See Shinto and Knapp]. The chemistry 
of the perrhenate obtained from the 188W/188Re 
generator is similar to pertechnetate, and similar 
targeted agent chemical strategies can be used, and 
many advances have been reported. However, in 
comparison with the well-established and very facile 
and usually simple attachment of +3Y and radioactive 
trivalent lanthanides to both acyclic, and especially 
cyclic polyamines such as DOTA, attachment of 188Re 
generally requires less straight forward and more 
complex radiochemistry. 
6.3. Availability of Preformed “Kits” for Radio- 
pharmacy Preparation of 188Re-Targeting Agents 
In addition to the availability of sufficiently high 
specific activity reactor-produced 188W and GMP 
manufactured generators, another challenge has been 
developing/optimizing the required radiochemistry for 
stable attachment/introduction of 188Re to targeting 
molecules. For the ease and dependable routine 
preparation of radiopharmaceuticals the use of 
sterile/pyrogen-free substrate/radiolabeling mixtures 
(“kits”) offers many advantages for quality, dependable 
and easy preparation. In the context of this issue of 
IJNMR, several useful “kits” have been recently 
developed for preparation of 188Re-labeled 
radiopharmaceuticals, and include kits for 
radiopharmacy preparation of HEDP for bone pain 
palliation [72-76], and Lipiodol analogues (DEDC, Re-
SSS) for treatment of inoperable hepatic carcinoma 
[77-78]. It would be expected that further development 
of new “kits” will be reported if the expected expanded 
clinical use of other attractive 188Re radiophar- 
maceuticals progresses. A major practical advantage 
for clinical use of 188Re is the potential, but low, non-
target tissue toxicity of 188Re-perrehnate, since 
decomposition and any release of 188Re from the 
targeting molecules results in vivo re-oxidation to 
perrhenate, which is rapidly excreted via the urinary 
bladder. If necessary, either Lugol’s or perchlorate can 
be administered for thyroid blocking. Later in this issue 
the details, advantages and various methods for 
attachment of188Re to radiopharmaceuticals are 
described in more detail. 
6.4. Use of the 188W/188Re Generator System in the 
Radiopharmacy 
One of the most efficient models would be 
installation of the 188W/188Re and an automated 
handling system in a centralized specialized facility for 
patient referral from local institutions. Because patient 
throughput for 188Re therapy is generally limited, use of 
the 188W/188Re generators is rarely optimized, and for 
this reason unit dose costs of 188Re are generally much 
higher than would be expected if the generators were 
efficiently used in large institutions or localized for multi 
institutional distribution of 188Re.  
6.5. Automated Elution/Concentration Systems to 
Ensure Consistency of Generator Performance and 
Reduced Staff Radiation Exposure 
The development of both in house constructed and 
commercially available automated systems for 
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synthesis, purification and dispensing of radiophar- 
maceuticals was initially most aggressively pursued 
and developed for routine high yield and reproducible 
GMP preparation of agents radiolabeled with positron-
emitting radioisotopes. Recently, these systems have 
been more recently widely available commercially and 
can be readily adapted for preparation of a wide range 
of radiopharmaceuticals and have been demonstrated 
to be particularly well suited for preparation of 
therapeutic agents where the same issues of 
reproducibility, quality (GMP) and dose reduction of 
technical staff are key considerations. Since the 188W 
product specific activity cannot be increased beyond 
about 10 Ci/gram W [13-18], as described earlier, the 
availability of effective and inexpensive post elution 
188Re bolus concentration methods allow a significant 
increase in generator useful shelf life. Use of the post 
elution concentration technology is well entrenched in 
the literature, well suited for automation and is straight 
forward and well established. The concentration units 
also require GMP manufacture and assembly and 
packaging. Generator and radiolabeling operation in 
hospital-based or for centralized radiopharmacy offers 
the opportunity for on demand availability of 188Re for 
various therapeutic applications. Such automated 
systems have been described for preparation/ 
concentration of the 188Re-perrhenate precursor  
[79-81], 188Re-MAG3 [82-87] and 188Re-Lipiodol-based 
agents for liver cancer therapy [88-89]. Figure 5 
illustrates a TADDEO automated system which is in 
use for the preparation of the 188Re-SSS-Lipiodol 
agent.  
6.6. Generator Manufacture under Good Manufac- 
turing Process (GMP) Conditions 
For routine use of 188Re in the clinical arena the 
188W/188Re generators must be manufactured under 
GMP conditions, which of course requires the 
availability of a sophisticated quality production facility 
and capabilities. Although, in addition to insuring 
patient safety, the generator production costs are high. 
DISCUSSION 
The routine commercial availability of 188W/188Re 
generators in Europe, India and elsewhere, is an 
important issue which will hopefully catalyze expanded 
clinical introduction of 188Re-labeled radiopharma- 
ceuticals in other countries. It is clear that all the 
“infrastructure” factors and associated required 
technologies are now available to offer revitalization for 
expanded use of 188Re-labeled radiopharmaceuticals 
for routine clinical use. In addition to the attractive 
radionuclidic and chemical properties and relatively low 
and generally accepted188Re perrhenate radiotoxicity to 
non-target organs, one of the principal factors which 
has stimulated interest in the therapeutic applications 
of 188Re is the routine, on demand availability from 
188W/188Re generators available in hospital-based or 
centralized radiopharmacies. However, to date 
apparent non-optimization of generator use – as 
illustrated by IAEA-sponsored clinical programs with 
188Re therapy for treatment of inoperable liver cancer 
and for inhibition of coronary restenotic hyperplasia 
after PTCA - has been a recurring factor. Two key 
challenges which must be overcome for more cost 
 
Figure 5: Flowchart of the TADDEO module for the preparation of188Re-SSS/Lipiodol. Courtesy of N. Lepareur, Rennes, 
France. 
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effective clinical use of 188Re thus include significant 
increase in single- and multi-institutional generator use 
for reduction of the resulting much higher unit dose 
costs, which are inconsistent taking into consideration 
of the long useful generator shelf-life of several months 
(i.e. 188W half-life = 69 days). Nearly all the reported 
single and multi-institutional clinical studies have not 
optimized 188W/188Re generator use, presumably 
because of the low patient trial recruitment and minimal 
referrals from local institutions. Since all the 
radiopharmacy issues for automation, 188Re bolus 
concentration, quality control, etc., have been 
developed and are widely available, it may be expected 
that much greater interest in the utility and therapeutic 
benefits of 188Re for targeted therapy would greatly 
increase if the generators were efficiently used and the 
unit dose costs would substantially decrease. In the 
opinion of this author, the most cost effective use of the 
188W/188Re generator to provide 188Re for clinical use 
would involve generator installation in a hospital-based 
or centralized radiopharmacy with the capability for 
188Re bolus concentration which would significantly 
extend the useful generator shelf-life and reduce 188Re 
unit dose cost. From a clinical use perspective, 
centralized units should focus on multiple therapeutic 
applications of 188Re instead of single use studies, 
since this would accelerate generator use. Also, to 
insure adequate patient throughput for therapeutic use 
of 188Re, referral of patients to such a centralized site 
would enhance generator utilization and reduce the 
high costs currently encountered with use of this 
generator system. The advantages for clinical 
applications of 188Re-labeled therapeutic agents have 
been recognized and are in progress in Europe and 
many countries in the Indian sub-continent and Asia, 
and hopefully this interest will expand and even be 
introduced into the U.S. and elsewhere. 
The progress and improvements which have been 
made in 188Re radiopharmaceutical development, 
important clinical applications in nuclear medicine and 
oncology, automation and bolus concentration would 
be expected to re-stimulate production, distribution and 
use of the 188W/188Re generator. While 4-5 institutions/ 
commercial entities had produced and distributed these 
generators several years ago, apparently only 2-3 
manufacturers now provide the 188W/188Re generators 
(Table 1). As well established in both the radiophar- 
maceutical and clinical literature, although 188Re has 
excellent radionuclidic properties and routine 
availability from a long shelf life generator, the cost and 
availability of the 188W/188Re generators are two issues 
which have apparently limited the expected further 
widespread clinical introduction of 188Re. In addition, 
one may argue that another issue associated with the 
under-utilization of 188Re may be the chemical 
challenges for facile introduction of 188Re into 188Re-
targeting molecules. The transition metal chemistry of 
NCA perrhenate is similar to the well described 
chemistry for pertechnetate [62-64], but there are 
distinct differences, which include the requirement for 
stronger reducing conditions for the conversion of 
perrhenate [Re(VII)] to Re(V). In addition, care that 
must be taken to avoid re-oxidation of Re(V) by the use 
of inert conditions and often by introduction of various 
antioxidant agents during the radiolabeling procedures 
(gentissic acid, etc.). Chemical attachment of 188Re in 
comparison with other therapeutic radionuclides, 
moreover, requires reaction conditions which are much 
more facile for radiolabeling acyclic chelators and cyclic 
multi-dentate chelators such as DOTA with trivalent 
M+3 metals, for instance, such as 177Lu [91]. 
Radiolabeling with 177Lu generally involves simple 
combination of the radioisotope and chelator solutions 
with perhaps some heating which is sufficient for high 
yield formation of the desired targeting agents. These 
techniques are much easier, facile and straight forward 
than the general radiolabeling conditions required for 
introduction of188Re into radiopharmaceuticals. 
Although 188Re may represent in some sense a “poor 
man’s 90Y” [91], from many perspectives use of 188Re 
has many advantages in comparison to the use of 90Y 
for many therapeutic applications, because of its 
potential expected cost effective availability from an in 
house generator and the emission of gamma photons 
for imaging, which would certainly be accepted as 
important in the evolving arena of personalized 
medicine. Because of safety and quality concerns, 90Y 
is evidently only generally available from 90Sr/90Y 
generators installed at central manufacturing sites, thus 
imposing logistics and scheduling challenges as well as 
high unit dose costs, for instance, for HCC treatment. 
Since the commercial manufacturing of 188W/188Re 
generators would be expected to be readily expanded, 
the major challenges for broader routine reimbursed 
clinical use of 188Re-labeled radiopharmaceuticals will 
of course now be dependent on major investments 
required for development, regulatory approval and 
introduction of new 188Re-labeled therapeutic agents.  
CONCLUSIONS 
In spite of these challenges, interest in the use of 
188Re continues on an international basis and 
continued important advances are being reported for 
188Re radiopharmaceutical targeting strategies and for 
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substrate radiolabeling. These advances and important 
descriptions of the excellent clinical outcomes using 
188Re-labeled radiopharmaceuticals for liver cancer 
therapy, bone pain palliation and other therapeutic 
applications are described in this issue of the 
International Journal of Nuclear Medicine and 
Research, and underline the importance of continuation 
of studies focused on the development and evaluation 
of 188Re-labeled agents. 
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